- Home
- MIST vs GNTA Comparison
MIST vs GNTA Comparison
Compare MIST & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | GNTA |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | Canada | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.4M | 62.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIST | GNTA |
|---|---|---|
| Price | $1.21 | $0.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 32.7K |
| Earning Date | 05-13-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,915.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.55 |
| 52 Week High | $3.06 | $10.00 |
Technical Indicators
Market Signals| Indicator | MIST | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 33.21 |
| Support Level | $1.20 | $0.58 |
| Resistance Level | $1.42 | $1.70 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 77.08 | 8.45 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.